ABIOMED, Inc. (NASDAQ:ABMD) Stake Reduced by Point72 Asset Management L.P.

Point72 Asset Management L.P. reduced its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 38.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 56,700 shares of the medical equipment provider’s stock after selling 35,900 shares during the period. Point72 Asset Management L.P. owned about 0.13% of ABIOMED worth $7,099,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ABMD. Creative Planning boosted its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 129 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new position in ABIOMED during the first quarter worth about $200,000. Palladium Partners LLC purchased a new position in ABIOMED during the first quarter worth about $211,000. Campbell & CO Investment Adviser LLC purchased a new position in ABIOMED during the first quarter worth about $231,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of ABIOMED during the first quarter worth $244,000. Hedge funds and other institutional investors own 90.77% of the company’s stock.

ABIOMED, Inc. (NASDAQ:ABMD) traded up 2.29% on Friday, hitting $146.25. 375,370 shares of the stock traded hands. The company has a market capitalization of $6.42 billion, a PE ratio of 85.53 and a beta of 0.20. The firm has a 50-day moving average price of $143.37 and a 200-day moving average price of $128.14. ABIOMED, Inc. has a 12 month low of $95.14 and a 12 month high of $149.34.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The company had revenue of $132.47 million during the quarter, compared to analysts’ expectations of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. ABIOMED’s revenue for the quarter was up 28.6% on a year-over-year basis. During the same period last year, the business earned $0.29 EPS. Analysts forecast that ABIOMED, Inc. will post $1.81 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “ABIOMED, Inc. (NASDAQ:ABMD) Stake Reduced by Point72 Asset Management L.P.” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/30/point72-asset-management-l-p-decreases-position-in-abiomed-inc-nasdaqabmd-updated-updated-updated.html.

A number of equities research analysts have recently weighed in on ABMD shares. Piper Jaffray Companies raised shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 target price on the stock in a research note on Thursday, April 6th. BidaskClub lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 28th. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Morgan Stanley reissued an “equal weight” rating and set a $140.00 price objective (up previously from $135.00) on shares of ABIOMED in a research note on Monday, July 10th. Finally, William Blair reissued an “outperform” rating on shares of ABIOMED in a research note on Thursday, June 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. ABIOMED has an average rating of “Buy” and an average target price of $154.00.

In other ABIOMED news, VP Michael G. Howley sold 600 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $132.84, for a total transaction of $79,704.00. Following the completion of the transaction, the vice president now directly owns 48,305 shares of the company’s stock, valued at approximately $6,416,836.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael G. Howley sold 18,279 shares of ABIOMED stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the transaction, the vice president now directly owns 62,105 shares of the company’s stock, valued at $8,294,743.80. The disclosure for this sale can be found here. Insiders sold a total of 53,629 shares of company stock valued at $7,072,580 over the last quarter. 7.00% of the stock is owned by company insiders.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply